Shares of Electra Therapeutics, Inc. (NASDAQ:ETRA – Get Free Report) have been assigned a consensus recommendation of “Buy” from the six brokerages that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $34.67.
A number of equities analysts have issued reports on ETRA shares. JPMorgan Chase & Co. began coverage on Electra Therapeutics in a report on Thursday. They issued an “overweight” rating and a $36.00 target price for the company. Evercore began coverage on Electra Therapeutics in a research note on Tuesday, October 13th. They set an “outperform” rating and a $36.00 price target on the stock. Jefferies Financial Group assumed coverage on Electra Therapeutics in a report on Tuesday, October 13th. They set a “buy” rating and a $32.00 price target on the stock. Wall Street Zen upgraded Electra Therapeutics to a “hold” rating in a report on Saturday, September 26th. Finally, Cantor Fitzgerald assumed coverage on Electra Therapeutics in a research note on Tuesday, October 13th. They issued an “overweight” rating for the company.
Get Our Latest Analysis on Electra Therapeutics
Electra Therapeutics Trading Up 2.2%
NASDAQ ETRA opened at $9.25 on Friday. Electra Therapeutics has a twelve month low of $8.50 and a twelve month high of $15.50.
Insider Activity at Electra Therapeutics
In other Electra Therapeutics news, Director Carl Gordon bought 1,333,333 shares of Electra Therapeutics stock in a transaction on Monday, September 21st. The shares were purchased at an average cost of $15.00 per share, with a total value of $19,999,995.00. Following the acquisition, the director directly owned 5,126,891 shares of the company’s stock, valued at $76,903,365. The trade was a 35.15% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Orbimed Advisors Llc bought 1,333,333 shares of Electra Therapeutics stock in a transaction on Monday, September 21st. The shares were acquired at an average cost of $15.00 per share, for a total transaction of $19,999,995.00. Following the completion of the acquisition, the director directly owned 5,126,891 shares in the company, valued at approximately $76,903,365. The trade was a 35.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.
About Electra Therapeutics
Electra Therapeutics, Inc (NASDAQ: ETRA) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate the immune system. The company’s research is directed toward selectively influencing immune-cell activity to address serious diseases, including cancer and autoimmune conditions.
Electra Therapeutics is advancing a pipeline of investigational medicines based on its immune-cell modulation approach. Its programs are intended to improve the body’s ability to recognize, control, or eliminate disease-associated cells while limiting effects on healthy tissue.
Featured Stories
- Five stocks we like better than Electra Therapeutics
- Is Texas Instruments Setting Up for Its Next Big Breakout?
- Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow
- Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was
- Tesla’s Flying-Car Hype Hits an Earnings Reality Check
Receive News & Ratings for Electra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
